Ruben Mesa: Excited by the top-line results of SURPASS-ET study
Ruben Mesa, President and Executive Director of Atrium Health Levine Cancer Institute, shared a post on LinkedIn:
“As a co-principal investigator, I am deeply excited by the top-line results for SURPASS-ET of RO Pegylated Interferon Alpha 2b meeting the primary endpoint of count control and secondary endpoint of JAK2 allel burden decrease compared to anagrelide for second-line therapy in essential thrombocythemia.”
More posts featuring Ruben Mesa.
Dr. Ruben A. Mesa, MD, FACP, serves as the President and Executive Director of Atrium Health Levine Cancer Institute (LCI) and Atrium Health Wake Forest Baptist Comprehensive Cancer Center. Additionally, he holds the position of vice dean for cancer programs and professor of medicine at Wake Forest University School of Medicine.
He is an international expert in hematologic cancers, particularly myeloproliferative neoplasms (MPNs). Through his tireless efforts, Dr. Mesa continues to drive progress in the understanding and treatment of hematologic malignancies, offering hope to those affected by these complex diseases.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023